



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, April 21st, 2016
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

Bryan Larson, PharmD	Jameson Rice, PharmD
Elizabeth Young, PharmD	Keith Tolman, MD
Clayton Grace, RPh	
Susan Siegfried, MD	

Committee Members Excused:

Ellie Brownstein, MD	Clinton Sheffield, MD
----------------------	-----------------------

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD	Chad Hope, PharmD
Merelynn Berrett, RN	Megan Schlappi, CPhT
Heather Santacruz, RN	Alyssa Pitts, RN

University of Utah Drug Regimen Review Center Staff Present:

Melissa Archer, PharmD

Other Individuals Present:

Joanne Lafleur, UofU	Peter Yoon, Johnson & Johnson
Roy Lindfield, Sunovion	Kristin Pareja, Otsuka
April Grant, Sunovion	B. Todd Thatcher, DO
Lyle Laird, Sunovion	Jamie Justice, NAMI Utah
Krystal Joy, Otsuka	Abril Atherton, VA Salt Lake City
Diana Santiago, Otsuka	Sean Mcbun, Allegen
Jason Lynn, Lundbeck	Scott Latimer, Sunovion
Charissa Anne, Johnson & Johnson	Whitney S, Johnson & Johnson
Tom Burgoyne, Otsuka	Lori Howarth, Bayer
Sam Vincent, 4 th Street Clinic	Pam Bennett, DSAMIF
Dan P, Otsuka	Tim Davis

Meeting conducted by: Bryan Larson, PharmD

1. **Welcome & Housekeeping:** Bryan Larson opened the meeting and reminded everyone to sign in.
2. **Review and Approval of March Minutes:** Bryan Larson made a motion to approve the minutes from March. Susan Siegfried seconded the motion. All in favor.
3. **Atypical Antipsychotics:** Melissa Archer presented a review of Atypical Antipsychotics.

She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data. Abril Atherton, a clinical pharmacist in Psychiatry who works at the Salt Lake City VA hospital discussed her work in the inpatient psychiatry unit and their utilization of antipsychotic medications.

4. Public Comment:

- a. Samuel Vincent, APRN- Samuel Vincent works at the 4th Street Clinic which serves the homeless population. He discussed the need for long acting injectables to be available for his patients.
- b. B. Todd Thatcher, DO- Dr. Thatcher works closely with recently incarcerated patients. He discussed the need for long acting injectables to be available for his patients.
- c. Kristin Pareja, PharmD- Kristin Pareja discussed the long acting injectables Abilify Maintena and Rexulti. She discussed their uses, efficacy and safety, and side effects.
- d. Peter Yoon, Pharm D- Peter Yoon discussed a study that had been done with recently incarcerated patients. He said that some patients were given oral antipsychotics while others were given the long acting injectables. He explained that the results were clear that long acting injectables helped significantly more than oral medications.
- e. Jamie Justice, MSW- Jaime Justice discussed her work with families affected by mental health disorders. She explained to the board that different people will need different treatment options, and asked that patients have access to all mental health medications.

5. Other State Report: Bryan Larson reported PDL listings for agents in this class in other States Medicaid programs.

6. Board Discussion

- a. Susan Siegfried asked Peter Yoon from Johnson & Johnson about injection site reactions with some of the long acting injectable medications. He explained that inactive ingredients in the medication or a mistake by the nurse/doctor injecting the drug into the patient could explain the injection site reactions that have been reported.
- b. Bryan Larson asked Peter Yoon if the study he discussed earlier involving incarcerated patients was a prospective or retrospective study. Peter Yoon replied that it was a randomized prospective study.
- c. Susan Siegfried made a motion that clozapine be a preferred medication on the PDL with no prior authorization criteria. Keith Tolman seconded. All in favor.
- d. Bryan Larson made a motion that at least one long acting injectable be preferred on the PDL. Jameson Rice seconded. All in favor.
- e. Elizabeth Young stated that there did not appear to be any strong differences in terms of efficacy amongst the 2nd generation oral antipsychotic medications. She did note that there were some safety concerns for certain populations, but that was an issue that should be discussed by the DUR board.
- f. Elizabeth Young made a motion that all 2nd generation oral antipsychotics are equally effective. Keith Tolman seconded. All in favor.

7. **Meeting Adjourned:** Bryan Larson motion to adjourn the meeting. Elizabeth Young seconded. All in favor.
8. Next meeting is scheduled for May 19, 2016. ADHD Stimulants will be discussed.

Minutes prepared by Megan Schlappi, CPhT

Recording available upon request, send email to medicaidpharmacy@utah.gov